Tag: ORATORIO

Ocrelizumab significantly reduces new/enlarging cortical lesions

Presented By
Prof. Michael Dwyer, University at Buffalo, NY, USA
Trial
Phase 3, ORATORIO
Conference
ACTRIMS 2025
Type
News article

28 March 2025 11:19

Ocrelizumab shows long-term benefits in primary progressive MS

Presented By
Prof. Jerry S. Wolinsky, University of Texas Health Science Center at Houston, TX, USA
Trial
Phase 3, ORATORIO
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 15:39

Long-term suppression of MRI disease activity with ocrelizumab

Presented By
Dr Douglas Arnold, McGill University, Canada
Trial
Phase 3, OPERA I/II, ORATORIO
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 14:30

ECTRIMS 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Trial
COMBAT-MS, SAkuraSky, SAkuraStar, ULTIMATE I and II, ORATORIO
Conference
ECTRIMS 2021

1 November 2021 08:32

Less thalamic atrophy in patients initiating ocrelizumab earlier

Conference
MS Virtual
Type
Peer-reviewed article

25 November 2020 16:59

Sustained reduction in disability progression with ocrelizumab

Presented By
Prof. Jerry Wolinsky, University of Texas, USA
Trial
Phase 3, ORATORIO
Conference
ECTRIMS 2019
Type
Peer-reviewed article

8 November 2019 19:32

Serum immunoglobulin levels and risk of serious infections

Presented By
Prof. Tobias Derfuss, University Hospital Basel, Switzerland
Conference
ECTRIMS 2019
Type
Peer-reviewed article

8 November 2019 19:23

Biotin, ocrelizumab, and ibudilast in progressive MS

Expert
Dr Andrew Goodman, University of Rochester School of Medicine and Dentistry, USA
Trial
ORATORIO, Phase 3; SPRINT-MS, Phase 2; MS-SPI, Phase 3
Conference
AAN 2019
Type
Peer-reviewed article

30 July 2019 19:15
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com